Akero Therapeutics, Inc.

AKRO

Akero Therapeutics, Inc.

AKRO

Insider Sentiment (TTM):

Last Purchase:2025-03-27Last Sale:2025-10-10Shares Purchased (TTM):0Shares Sold (TTM):142,253

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:57Shares Outstanding:82,008,267Institutional Ownership Pct.:0.00%

Earnings Market Reaction:

Filing Date:2025-11-07Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Cash And Cash Equivalents At Carrying Value	176	220	186	340	316	310	624	234	270	444	258	250
Assets Current
Assets Current	755	765	713	770	747	776	911	560	576	643	347	355
Marketable Securities Current	562	522	500	403	401	450	280	316	285	195	85	102
Prepaid Expense And Other Assets Current	17	22	27	27	30	16	8	10	21	4	4	4
Marketable Securities Noncurrent	250	344	442	55	70	88	-	19	58	19	-	-
Property Plant And Equipment Net	-	-	-	-	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Assets	1,006	1,109	1,156	826	818	865	912	580	635	664	349	357
Liabilities And Stockhold…
Accounts Payable Current	20	13	11	9	25	15	14	7	11	10	7	8
Liabilities Current
Liabilities Current	48	60	42	40	43	31	30	19	28	22	17	19
Loans Payable Current	-	-	-	-	-	-	-	-	2	-	-	-
Long Term Loans Payable	-	22	29	35	35	35	35	25	23	25	25	10
Derivative Liabilities Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	1	1	1	1	1	1	1	1	1
Liabilities	48	83	72	76	79	67	66	45	52	47	42	30
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,005	1,992	1,980	1,575	1,492	1,482	1,474	1,109	1,103	1,096	754	749
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of…	2	1	1	1	2	-0	-0	0	-1	-0	0	0
Stockholders Equity	958	1,026	1,084	750	738	798	846	535	583	616	306	327
Retained Earnings Accumulated Deficit	-1,049	-967	-897	-826	-756	-683	-627	-574	-519	-479	-448	-422
Liabilities And Stockholders Equity	1,006	1,109	1,156	826	818	865	912	580	635	664	349	357
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	80	80	80	72	70	69	69	56	56	56	47	47
Shares Outstanding	80	80	80	72	70	69	69	56	56	56	47	47

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	30.70%	24.66%	16.47%	-7.39%	-5.39%	6.56%	0.59%	-	-	-	-	-
2024	-4.22%	19.39%	43.10%	9.94%	14.15%	18.55%	-6.82%	-18.00%	-24.01%	-7.94%	-23.39%	-20.87%
2023	10.02%	-8.38%	-8.76%	4.61%	6.37%	-76.07%	39.93%	60.85%	46.55%	-6.89%	-23.08%	-26.19%
2022	-	-	-	-	-	-	-	-	-	-7.85%	12.18%	16.16%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Performance and Valuation Metrics

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	15.83	12.66	16.80	19.38	17.25	24.89	30.12	29.27	20.25	29.78	20.84	18.61
Quick Ratio	15.48	12.29	16.17	18.69	16.57	24.39	29.86	28.75	19.50	29.60	20.58	18.42
Working Capital	706.88M	704.20M	670.71M	730.63M	703.60M	744.84M	881.02M	540.83M	547.53M	621.60M	330.81M	336.09M
Leverage & Debt
Debt to Equity	0.05	0.08	0.07	0.10	0.11	0.08	0.08	0.08	0.09	0.08	0.14	0.09
Interest Coverage TTM	-71.46	-67.37	-63.41	-61.14	-61.69	-58.44	-56.17	-55.78	-53.20	-62.95	-98.54	-155.83
Debt Ratio	0.05	0.08	0.06	0.09	0.10	0.08	0.07	0.08	0.08	0.07	0.12	0.08
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-3.57	-3.47	-3.43	-3.75	-3.42	-2.95	-3.02	-2.89	-2.15	-2.23	-2.38	-2.87
Free Cash Flow Per Share TTM	-3.05	-3.10	-3.34	-3.43	-3.05	-2.76	-2.63	-2.77	-2.20	-1.87	-2.01	-2.37
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	23.44%	39.08%	50.30%	66.09%	98.29%	76.75%	60.30%	35.46%	-1.45%	4.84%	0.11%	11.17%
EPS Growth (1Y)	4.52%	17.70%	13.33%	30.05%	58.80%	32.56%	26.88%	0.46%	-31.49%	-28.48%	-25.35%	-0.69%
Calculated Values
Free Cash Flow TTM	-250.17M	-253.42M	-262.63M	-230.11M	-211.64M	-190.94M	-155.88M	-145.37M	-122.25M	-97.15M	-94.27M	-92.52M
Net Debt	-176.03M	-220.45M	-185.92M	-340.24M	-316.07M	-310.36M	-623.85M	-234.21M	-267.47M	-444.16M	-257.99M	-249.88M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2025-10-10Sale

Owner: Cheng, Andrew

Title: President and CEO

Shares: 30,000

Price/Share: $53.98

Value: $1,619,400.00

Shares Owned: 526,114

Relationship: Director,Officer

Ownership: Direct

2025-10-07Sale

Owner: Rolph, Timothy

Title: Chief Scientific Officer

Shares: 12,500

Price/Share: $46.42

Value: $580,250.00

Shares Owned: 166,571

Relationship: Officer

Ownership: Direct

2025-10-01Sale

Owner: Young, Jonathan

Title: Chief Operating Officer

Shares: 12,500

Price/Share: $47.81

Value: $597,625.00

Shares Owned: 196,898

Relationship: Officer

Ownership: Direct

2025-09-11Sale

Owner: Young, Jonathan

Title: Chief Operating Officer

Shares: 586

Price/Share: $43.02

Value: $25,209.72

Shares Owned: 196,898

Relationship: Officer

Ownership: Direct

2025-09-11Sale

Owner: Yale, Catriona

Title: Chief Development Officer

Shares: 659

Price/Share: $43.02

Value: $28,350.18

Shares Owned: 90,829

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-10-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	53.98	$1,619,400.00	526,114	4
2025-10-07	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	46.42	$580,250.00	166,571	4
2025-10-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	12,500	47.81	$597,625.00	196,898	4
2025-09-11	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	586	43.02	$25,209.72	196,898	4
2025-09-11	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	659	43.02	$28,350.18	90,829	4
2025-09-11	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	553	43.02	$23,790.06	166,571	4
2025-09-11	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,796	43.02	$77,263.92	473,902	4
2025-09-11	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	659	43.02	$28,350.18	57,752	4
2025-09-08	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	44.53	$556,625.00	167,124	4
2025-09-02	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	12,500	46.83	$585,375.00	197,484	4
2025-08-12	Henderson, Jane	Director	-	Direct	Sale	3,000	47.46	$142,380.00	9,398	4
2025-08-12	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	12,500	48.02	$600,250.00	197,484	4
2025-08-11	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	48.79	$1,463,700.00	490,757	4
2025-08-05	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	49.28	$616,000.00	167,124	4
2025-07-16	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	53.17	$531,700.00	91,488	4
2025-07-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	51.15	$1,534,500.00	520,757	4
2025-07-07	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	51.85	$648,125.00	167,124	4
2025-07-01	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	2,000	52.88	$105,760.00	29,891	4
2025-06-20	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	875	54.59	$47,766.25	31,698	4
2025-06-18	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	1,633	54.84	$89,553.72	90,598	4
2025-06-18	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	1,453	54.84	$79,682.52	196,594	4
2025-06-18	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	1,129	54.84	$61,914.36	166,234	4
2025-06-18	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	6,620	54.84	$363,040.80	549,867	4
2025-06-18	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	1,634	54.84	$89,608.56	57,521	4
2025-06-18	Gangloff, Scott A.	Officer	Chief Technology Officer	Direct	Sale	848	54.84	$46,504.32	23,452	4
2025-06-16	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	54.70	$547,000.00	92,231	4
2025-06-16	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	2,000	54.46	$108,920.00	32,573	4
2025-06-10	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	2,493	53.99	$134,597.07	198,047	4
2025-06-10	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	2,358	54.00	$127,332.00	167,363	4
2025-06-10	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	2,803	54.00	$151,362.00	92,231	4
2025-06-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	37,837	54.03	$2,044,333.11	556,487	4
2025-06-10	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	919	54.00	$49,626.00	32,573	4
2025-06-10	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	2,804	54.00	$151,416.00	59,155	4
2025-06-06	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	25,000	55.04	$1,376,000.00	169,721	4
2025-06-02	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	4,000	50.30	$201,200.00	33,492	4
2025-05-22	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	4,000	50.00	$200,000.00	33,492	4
2025-05-15	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	39.19	$391,900.00	95,034	4
2025-05-12	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	41.32	$1,239,600.00	594,324	4
2025-05-07	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	8,000	42.54	$340,320.00	33,492	4
2025-05-06	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	43.54	$544,250.00	169,721	4
2025-04-24	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	6,250	41.03	$256,437.50	169,721	4
2025-04-15	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	9,073	38.21	$346,679.33	95,034	4
2025-04-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	35.23	$1,056,900.00	624,324	4
2025-04-07	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	6,250	36.56	$228,500.00	169,721	4
2025-03-27	Graham, G. Walmsley	Director	-	Indirect	Purchase	50,000	43.55	$2,177,500.00	1,200,000	4
2025-03-17	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	44.88	$448,800.00	95,034	4
2025-03-12	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	614	44.88	$27,556.32	95,034	4
2025-03-12	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,738	44.88	$78,001.44	654,324	4
2025-03-12	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	676	44.88	$30,338.88	61,959	4
2025-03-12	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	516	44.88	$23,158.08	169,721	4
2025-03-12	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	607	44.88	$27,242.16	200,540	4
2025-03-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	42.03	$1,260,900.00	656,062	4
2025-03-05	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	12,500	44.65	$558,125.00	170,237	4
2025-03-04	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	50,000	44.62	$2,231,000.00	201,147	4
2025-03-03	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	1,000	48.09	$48,090.00	33,492	4
2025-02-18	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	50.21	$502,100.00	95,648	4
2025-02-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	53.74	$1,612,200.00	686,062	4
2025-02-05	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	18,750	56.62	$1,061,625.00	170,237	4
2025-02-03	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	10,000	53.82	$538,200.00	251,147	4
2025-01-30	Graham, G. Walmsley	Director	-	Indirect	Purchase	200,000	48.00	$9,600,000.00	1,000,000	4
2025-01-27	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	53,590	56.04	$3,003,183.60	95,648	4
2025-01-27	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	30,000	55.66	$1,669,800.00	716,062	4
2025-01-27	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	5,000	57.03	$285,150.00	33,492	4
2025-01-27	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	31,250	55.78	$1,743,125.00	170,237	4
2025-01-02	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	10,000	28.03	$280,300.00	218,083	4
2024-12-17	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	3,800	31.10	$118,180.00	178,337	4
2024-12-16	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	9,074	29.11	$264,144.14	95,648	4
2024-12-16	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	1,000	29.13	$29,130.00	34,258	4
2024-12-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	7,855	30.79	$241,855.45	597,562	4
2024-12-10	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	925	30.79	$28,480.75	17,858	4
2024-12-10	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	2,503	30.79	$77,067.37	203,783	4
2024-12-10	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	2,817	30.79	$86,735.43	38,335	4
2024-12-10	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	4,818	30.91	$148,924.38	178,337	4
2024-12-10	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	2,810	30.79	$86,519.90	71,348	4
2024-12-02	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	32.09	$802,250.00	605,417	4
2024-12-02	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	10,000	32.13	$321,300.00	206,286	4
2024-11-15	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	9,061	28.26	$256,063.86	74,158	4
2024-11-06	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	10,000	35.19	$351,900.00	74,158	4
2024-11-01	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	15,485	32.62	$505,120.70	74,158	4
2024-11-01	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	108,366	31.98	$3,465,544.68	605,417	4
2024-11-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	50,716	32.15	$1,630,519.40	216,286	4
2024-10-18	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	63,539	31.82	$2,021,810.98	605,417	4
2024-10-15	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	14,825	30.72	$455,424.00	75,294	4
2024-10-14	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	40,000	30.15	$1,206,000.00	226,286	4
2024-10-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	10,000	28.18	$281,800.00	226,286	4
2024-09-20	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,500	27.65	$152,075.00	75,294	4
2024-09-18	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	3,871	27.56	$106,684.76	75,294	4
2024-09-10	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	568	26.18	$14,870.24	236,286	4
2024-09-10	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	637	26.18	$16,676.66	75,294	4
2024-09-10	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	639	26.18	$16,729.02	41,152	4
2024-09-10	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	537	26.18	$14,058.66	180,705	4
2024-09-10	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,738	26.18	$45,500.84	605,417	4
2024-09-03	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	949	27.61	$26,201.89	75,931	4
2024-09-03	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	27.00	$135,000.00	236,854	4
2024-08-27	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	23,175	26.41	$612,051.75	41,791	4
2024-08-26	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,200	27.51	$143,052.00	75,931	4
2024-08-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	26.84	$134,200.00	241,854	4
2024-07-25	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	22,272	27.33	$608,693.76	41,791	4
2024-07-16	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	34,811	28.05	$976,448.55	41,791	4
2024-07-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	23.40	$117,000.00	246,854	4
2024-06-11	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	2,825	22.64	$63,958.00	74,867	4
2024-06-11	Lamy, Patrick	Officer	Senior VP, Commercial Strategy	Direct	Sale	569	22.64	$12,882.16	18,562	4
2024-06-11	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	2,516	22.64	$56,962.24	250,790	4
2024-06-11	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	7,894	22.64	$178,720.16	581,553	4
2024-06-11	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	2,380	22.64	$53,883.20	180,178	4
2024-06-11	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	2,831	22.64	$64,093.84	46,799	4
2024-06-03	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	19.29	$96,450.00	253,306	4
2024-05-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	20.15	$100,750.00	258,306	4
2024-04-01	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,000	24.68	$123,400.00	263,306	4
2024-03-13	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,969	28.33	$55,781.77	589,447	4
2024-03-13	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	651	28.33	$18,442.83	268,306	4
2024-03-13	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	723	28.33	$20,482.59	77,692	4
2024-03-13	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	724	28.33	$20,510.92	49,630	4
2024-03-13	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	619	28.33	$17,536.27	182,558	4
2024-03-04	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	20,646	35.49	$732,726.54	78,415	4
2024-03-04	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	75,000	33.98	$2,548,500.00	591,416	4
2023-12-27	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	5,414	24.00	$129,936.00	185,131	4
2023-12-14	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	514	20.76	$10,670.64	182,672	4
2023-12-14	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,628	20.76	$33,797.28	550,911	4
2023-12-14	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	611	20.76	$12,684.36	50,354	4
2023-12-14	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	543	20.76	$11,272.68	185,131	4
2023-12-14	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	597	20.76	$12,393.72	77,910	4
2023-12-11	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	7,405	20.02	$148,248.10	552,539	4
2023-12-08	Graham, G. Walmsley	Director	-	Indirect	Purchase	100,000	19.83	$1,983,000.00	800,000	4
2023-12-01	Graham, G. Walmsley	Director	-	Indirect	Purchase	50,000	16.99	$849,500.00	700,000	4
2023-11-17	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	30,000	14.68	$440,400.00	153,177	4
2023-10-02	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	490	51.10	$25,039.00	183,177	4
2023-10-02	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	48.35	$1,208,750.00	460,998	4
2023-09-21	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,000	48.10	$240,500.00	46,010	4
2023-09-19	Graham, G. Walmsley	Director	-	Indirect	Purchase	400,000	26.00	$10,400,000.00	400,000	4
2023-09-13	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	531	50.34	$26,730.54	150,689	4
2023-09-13	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	1,682	50.34	$84,671.88	460,998	4
2023-09-13	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	632	50.34	$31,814.88	18,468	4
2023-09-13	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	562	50.34	$28,291.08	183,177	4
2023-09-01	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	50.00	$1,250,000.00	462,680	4
2023-08-28	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,745	50.30	$288,973.50	46,627	4
2023-08-08	Graham, G. Walmsley	Director	-	Indirect	Purchase	25,000	42.06	$1,051,500.00	600,000	4
2023-08-01	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	43.18	$1,079,500.00	447,680	4
2023-08-01	Graham, G. Walmsley	Director	-	Indirect	Purchase	25,000	43.26	$1,081,500.00	575,000	4
2023-07-03	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	45.44	$1,136,000.00	447,680	4
2023-06-23	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	11,000	51.07	$561,770.00	46,627	4
2023-06-20	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	20,777	55.00	$1,142,735.00	19,100	4
2023-06-16	Heyman, Tomas J.	Director	-	Direct	Sale	26,000	54.67	$1,421,420.00	0	4
2023-06-16	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	78,200	55.32	$4,326,024.00	151,220	4
2023-06-16	Henderson, Jane	Director	-	Direct	Sale	40,000	54.12	$2,164,800.00	0	4
2023-06-13	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	591	55.16	$32,599.56	79,976	4
2023-06-13	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	606	55.16	$33,426.96	22,377	4
2023-06-13	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	509	55.16	$28,076.44	189,420	4
2023-06-13	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	1,613	55.16	$88,973.08	407,680	4
2023-06-13	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	538	55.16	$29,676.08	183,739	4
2023-06-01	Cheng, Andrew	Director,Officer	President and CEO	Direct	Sale	25,000	45.11	$1,127,750.00	409,293	4
2023-05-19	Graham, G. Walmsley	Director	-	Indirect	Purchase	120,000	42.00	$5,040,000.00	520,000	4/A
2023-05-01	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	25,000	45.25	$1,131,250.00	409,293	4
2023-04-03	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	25,000	38.36	$959,000.00	369,293	4
2023-03-01	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	25,000	46.44	$1,161,000.00	370,999	4
2023-02-01	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	25,000	49.46	$1,236,500.00	370,999	4
2023-01-13	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,000	50.54	$252,700.00	81,268	4
2023-01-03	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	25,000	52.54	$1,313,500.00	370,999	4
2023-01-03	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	8,777	54.64	$479,575.28	184,911	4
2022-12-29	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	20,316	50.96	$1,035,303.36	190,532	4
2022-12-28	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	999	49.76	$49,710.24	23,624	4
2022-12-27	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	12,500	49.57	$619,625.00	182,449	4
2022-12-12	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,000	43.48	$217,400.00	86,268	4
2022-12-01	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	10,000	46.07	$460,700.00	310,148	4
2022-12-01	Skorpios, Trust, Blue Hor…	Other	-	Indirect	Sale	1,636,000	43.50	$71,166,000.00	3,271,829	4
2022-11-30	Harrison, Seth Loring	Director	-	Direct	Sale	11,101	47.02	$521,969.02	136,301	4
2022-11-16	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	3,947	45.75	$180,575.25	183,837	4
2022-11-10	Yale, Catriona	Officer	Chief Development Officer	Direct	Sale	5,000	39.68	$198,400.00	72,073	4
2022-11-01	Cheng, Andrew	Director,Officer	President & CEO	Direct	Sale	10,000	43.21	$432,100.00	310,148	4
2022-10-28	Harrison, Seth Loring	Director	-	Direct	Sale	21,138	40.70	$860,316.60	147,402	4
2022-10-27	Harrison, Seth Loring	Director	-	Direct	Sale	66,426	42.13	$2,798,527.38	168,540	4
2022-10-26	Rolph, Timothy	Officer	Chief Scientific Officer	Direct	Sale	4,762	45.03	$214,432.86	190,922	4
2022-10-25	Young, Jonathan	Officer	Chief Operating Officer	Direct	Sale	12,500	44.72	$559,000.00	163,254	4
2022-10-13	White, William Richard	Officer	Chief Financial Officer	Direct	Sale	20,000	39.82	$796,400.00	4,429	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Institutional Ownership

No data available for chart

2025-12-31

0.00%

Inst. Shares: 57

Shares Outstanding: 82,008,267

2025-09-30

106.60%

Inst. Shares: 87,417,770

Shares Outstanding: 82,008,267

2025-06-30

106.39%

Inst. Shares: 86,941,771

Shares Outstanding: 81,721,387

2025-03-31

99.65%

Inst. Shares: 78,381,420

Shares Outstanding: 78,656,629

2024-12-31

101.11%

Inst. Shares: 67,883,154

Shares Outstanding: 67,136,772

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	57	82,008,267	0.00%
2025-09-30	87,417,770	82,008,267	106.60%
2025-06-30	86,941,771	81,721,387	106.39%
2025-03-31	78,381,420	78,656,629	99.65%
2024-12-31	67,883,154	67,136,772	101.11%
2024-09-30	67,115,530	69,442,136	96.65%
2024-06-30	65,352,754	69,160,484	94.49%
2024-03-31	67,542,274	59,307,759	113.88%
2023-12-31	54,807,050	52,568,159	104.26%
2023-09-30	52,153,646	55,613,120	93.78%
2023-06-30	50,898,131	51,867,854	98.13%
2023-03-31	43,602,458	46,944,059	92.88%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Akero Therapeutics, Inc. (AKRO) — SEC Financial Statements & Analysis

Akero Therapeutics, Inc. (AKRO) is a pharmaceutical preparations company, incorporated in DE. Akero Therapeutics, Inc. trades on AKRO: Nasdaq as: AKRO. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Akero Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.05x. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.05x

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Akero Therapeutics, Inc. in?

Akero Therapeutics, Inc. (AKRO) operates in the Pharmaceutical Preparations industry.

What exchange does AKRO trade on?

Akero Therapeutics, Inc. (AKRO) trades on the AKRO: Nasdaq.

Where is Akero Therapeutics, Inc. incorporated?

Akero Therapeutics, Inc. is incorporated in DE.

Akero Therapeutics, Inc. (AKRO) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.